Extremely expensive Biogen rare disease drug could invite tweet by President-elect Trump, analyst says
December 29, 2016 at 15:32 PM EST
At up to $750,000 in the first year, Spinraza could be ‘straw that breaks the camel’s back,’ one Wall Street analyst suggested.